Ken Griffin Novo Nordisk A S Call Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$85.0 - $120.04 $112 Million - $158 Million	1,317,800 Added 114.22%	2,471,500 $213 Million
Q3 2024 Nov 14, 2024	SELL	$119.07 - $145.42 $30.2 Million - $36.9 Million	-253,500 Reduced 18.01%	1,153,700 $137 Million
Q2 2024 Aug 14, 2024	BUY	$122.71 - $146.91 $6.26 Million - $7.49 Million	51,000 Added 3.76%	1,407,200 $201 Million
Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $43.2 Million - $57.5 Million	422,900 Added 45.31%	1,356,200 $174 Million
Q4 2023 Feb 14, 2024	SELL	$87.78 - $105.45 $4.94 Million - $5.94 Million	-56,300 Reduced 5.69%	933,300 $96.5 Million
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $43.1 Million - $94.5 Million	473,400 Added 91.71%	989,600 $90 Million
Q2 2023 Aug 14, 2023	BUY	$155.98 - $172.65 $21.3 Million - $23.6 Million	136,800 Added 36.06%	516,200 $83.5 Million
Q1 2023 May 15, 2023	SELL	$132.34 - $159.14 $4.21 Million - $5.06 Million	-31,800 Reduced 7.73%	379,400 $60.4 Million
Q4 2022 Feb 14, 2023	SELL	$102.55 - $135.33 $1.88 Million - $2.48 Million	-18,300 Reduced 4.26%	411,200 $55.6 Million
Q3 2022 Nov 14, 2022	BUY	$95.28 - $116.93 $17.9 Million - $22 Million	187,900 Added 77.77%	429,500 $42.8 Million

1,805

325M

11.4M

10.9M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $153B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.